Hepatic Encephalopathy Market to Procure from Ageing Population and Increased R&D Investments; Anticipated Steady Growth Boost at a CAGR of 5.31% During the Study Period 2018-2030, Evaluates DelveInsight

The growing market of Hepatic Encephalopathy is expected to surge mainly due to the rising prevalence of Hepatic Encephalopathy and ageing population, increased R&D activities and launch of upcoming therapies like Rifaximin, AXA1665, GR3027 with key pharmaceuticals such as Axcella Health, Umecrine Cognition, Vedanta Biosciences, and others.

LAS VEGAS, Oct. 27, 2021 /PRNewswire/ -- DelveInsight's Hepatic Encephalopathy Market report delivers an in-depth understanding of current treatment practices, emerging drugs, Hepatic Encephalopathy market share of the individual therapies, current and forecasted Hepatic Encephalopathy market size from 2018 to 2030 segmented into the 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].

Some of the key takeaways from the Hepatic Encephalopathy Market Report: 

• The Hepatic Encephalopathy market size was evaluated to be USD 1,448 million in 2020 in the 7MM market by DelveInsight.  The market size of Hepatic Encephalopathy is expected to grow at a CAGR of 5.31%  in the 7MM for the study period 2018-2030.
• According to an estimate by DelveInsight, the highest diagnosed Hepatic Encephalopathy prevalent cases in the 7MM were found in the United States with 205,018 cases in 2020.
• The increase in market size of Hepatic Encephalopathy is a direct consequence of the expected approval of emerging therapies and the increasing patient population of Hepatic Encephalopathy in the 7MM.
• The expected approval of potential therapies such as GR3027 (Golexanolone), Rifaximin (SSD), AXA1665, VE303 may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Hepatic Encephalopathy.
• Key pharma players working proactively in the Hepatic Encephalopathy therapeutic market are Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Health/Salix Pharmaceuticals and others that have the potential to create a significant positive shift in the market size. 
• According to DelveInsight's analysis, the diagnosed prevalent cases of Hepatic Encephalopathy in the 7MM is expected to increase at a CAGR of 0.61% for the study period of 2018-2030.

For further information on Market Impact by Therapies, Download Hepatic Encephalopathy Market sample @ Hepatic Encephalopathy Market Landscape 

Hepatic Encephalopathy: Overview

Hepatic Encephalopathy (HE) is a brain disorder that develops in people suffering from liver disease. Hepatic Encephalopathy presents a spectrum of neuropsychiatric symptoms that lie from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease.

It is found in Hepatic Encephalopathy, the incidence of acute liver failure, liver bypass procedures, and cirrhosis are categorized as Type A, B, and C Hepatic Encephalopathy, respectively. Also, Hepatic Encephalopathy can be classified according to whether it is present as overt or covert.

Request for a Webex demo of the report @ Hepatic Encephalopathy Market Scenario 

Hepatic Encephalopathy Epidemiology Segmentation

As per DelveInsight's analysis, the total diagnosed prevalent cases of Hepatic Encephalopathy in the 7MM were found to be 337,141 in 2020. Moreover, these cases are expected to increase by 2030 at a CAGR of 0.61% during the study period (2018–2030).

DelveInsight estimates that the majority of cases of Hepatic Encephalopathy are occupied by males as compared to females. There were a total of 149,048 male and 55,970 female cases of Hepatic Encephalopathy in 2020 in the United States.

The Hepatic Encephalopathy Report offers epidemiological analysis for the study period 2018-2030 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Hepatic Encephalopathy 
• Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy
• Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy
• Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy

Know how Hepatic Encephalopathy Epidemiological Trends are going to look like in 2030 for the 7MM by downloading @ Hepatic Encephalopathy Epidemiological Insights

Hepatic Encephalopathy Market

The current Hepatic Encephalopathy market includes treatment therapies like Nonabsorbable disaccharides (i.e., lactitol and lactulose) and nonabsorbable antibiotics (i.e., rifaximin) are the two primary forms of therapies for Hepatic Encephalopathy. The first-line agent used to prevent acute or persistent Hepatic Encephalopathy is the nonabsorbable disaccharides (lactulose or lactitol). The second-line agents include oral antibiotics (neomycin, metronidazole, and rifaximin) that can reduce urease-producing bacteria in the intestines, resulting in decreased ammonia production and absorption through the gastrointestinal tract. Xifaxan (rifaximin) tablets, developed and marketed by Salix Pharmaceuticals, are approved for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adults.

Novel and emerging Hepatic Encephalopathy treatment therapies are being developed by several pharmaceutical and biotech companies that are under different phases of clinical investigation. For example AXA1665, being developed by Axcella Health, is a candidate for a reduction in risk of recurrent Overt Hepatic Encephalopathy (OHE) is in Phase II stage of clinical development and is a composition of eight amino acids and derivatives which are supposed to target multiple metabolic pathways intersecting key organ systems, including the liver, muscle, and gut. Another breakthrough therapy, GR3027 (Golexanolone) in Phase I/IIa trial by Umecrine Cognition, is an orally administered small molecule to treat patients diagnosed with Hepatic Encephalopathy. 

Discover more about therapy set to grab substantial Hepatic Encephalopathy market share @ Hepatic Encephalopathy Market Share

Hepatic Encephalopathy Pipeline Therapies and Key Companies

• AXA1665: Axcella Health
• Rifaximin (SSD): Bausch Health/Salix Pharmaceuticals
• GR3027 (Golexanolone): Umecrine Cognition
• VE303: Vedanta Biosciences

To know about more pipeline therapies under different development phases visit @ Hepatic Encephalopathy Pipeline Assessment

Hepatic Encephalopathy Market Dynamics

The availability of well-established healthcare infrastructure in the 7MM contributes a lot to the growth of the Hepatic Encephalopathy market. In addition, an increasingly ageing population and increased R&D investments by drug manufacturing companies are fueling the Hepatic Encephalopathy market expansion. The overall market of the Hepatic Encephalopathy market is expected to boost due to the rising prevalence of Hepatic Encephalopathy over the globe and thus the surge in treatment options. An increase in patient and practitioner awareness regarding Hepatic Encephalopathy will lead to better patient outcomes and improved diagnostic opportunities. Along with these, the expected launch of emerging therapies will boost the Hepatic Encephalopathy treatment market in the forecasted period.

A high number of undiagnosed and unreported cases contribute to the lack of awareness of Hepatic Encephalopathy. Few adverse events associated with the current therapies, absence of a robust pipeline, and lack of effective treatment, contribute as setbacks in the Hepatic Encephalopathy market. Various challenges are experienced in the diagnosis of Hepatic Encephalopathy as well as disease burden acts as an underlying cause for lack of awareness regarding this condition.

Know which therapy is expected to score the touchdown first @ Hepatic Encephalopathy Market Landscape and Forecast

Scope of the Hepatic Encephalopathy Report

• Study Period: 2018–2030
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Companies: Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Health/Salix Pharmaceuticals
• Key Hepatic Encephalopathy Pipeline Therapies: Rifaximin (SSD), AXA1665, GR3027 (Golexanolone), VE303
• Therapeutic Assessment: Hepatic Encephalopathy current marketed and emerging therapies
• Market Dynamics: Hepatic Encephalopathy market drivers and barriers 
• Competitive Intelligence Analysis: Porter's five forces, SWOT analysis, PESTLE analysis, BCG Matrix, Market entry strategies
• Key Cross Competition
• KOL's views
• Unmet Needs
• Market Access and Reimbursement

Explore more about the future market share of Hepatic Encephalopathy treatment therapies @ Hepatic Encephalopathy Market Forecast Outlook

Table of Contents 

Get in touch with our Business executive @ Hepatic Encephalopathy Market Analysis 

Learn more about report offerings @ Hepatic Encephalopathy Market Scenario 

Related Reports

Hepatic Colorectal Metastasis Pipeline 

"Hepatic - Colorectal Metastasis Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development pipeline scenario and growth prospects across the Hepatic - Colorectal Metastasis market with key companies involved like Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc, Umecrine Cognition, Mallinckrodt Therapeutics, Vedanta Biosciences, Patricia Bloom, and others.

Multiple Organ Dysfunction Syndrome Market

DelveInsight's "Multiple Organ Dysfunction Syndrome Market Insights, Epidemiology, and Market Forecast-2030" report proffers thorough details into the Memory Disorder market, epidemiology, pipeline therapies, and key companies including Dart Neuroscience, Corcept Therapeutics, Cerecin, and various others. 

Narcolepsy Market

DelveInsight's 'Narcolepsy–Market Insights, Epidemiology, and Market Forecast-2030' report provides deep insights into the Narcolepsy market, epidemiology, pipeline therapies, and key companies including Cephalon Inc., Jazz Pharmaceuticals, and several others.

Persistent Epithelial Defect Market

DelveInsight's "Persistent Corneal Epithelial Defects (PEDs) - Market Insights, Epidemiology, and Market Forecast - 2030" report provides a detailed overview of the disease. Key companies include Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, and others developing Persistent Epithelial Defect therapies. 

Tick-Borne Encephalitis Epidemiology

DelveInsight's "Tick Borne Encephalitis - Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical, and forecasted Tick-Borne Encephalitis epidemiology in the 7MM.

Browse through our Blog Posts

Hepatic Encephalopathy - Lack of active pipeline products

• Hepatic encephalopathy (HE) can be described as deterioration of brain function occurring due to the accumulation of toxic substances in the blood which ultimately reaches the brain. 

Hepatic Encephalopathy - An ailment of the liver to the brain

• Hepatic Encephalopathy (HE) can be described as deterioration of brain function occurring due to the accumulation of toxic substances in the blood which ultimately reaches the brain. 

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

• Hepatitis is an infection that causes inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis, or liver cancer. 

Assessing leakage for application of strategic counter by Competitive Intelligence 

About DelveInsight

DelveInsight is a pioneer in providing state-of-the-art services to clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com  
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg